Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Operating Expenses (2016 - 2025)

Arcadia Biosciences' Operating Expenses history spans 12 years, with the latest figure at -$32000.0 for Q4 2025.

  • For Q4 2025, Operating Expenses rose 97.45% year-over-year to -$32000.0; the TTM value through Dec 2025 reached $5.0 million, up 28.06%, while the annual FY2025 figure was $5.0 million, 28.11% up from the prior year.
  • Operating Expenses reached -$32000.0 in Q4 2025 per RKDA's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $16.0 million in Q4 2021 to a low of -$2.0 million in Q4 2023.
  • Average Operating Expenses over 5 years is $4.3 million, with a median of $3.0 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 4812.39% in 2021, then crashed 136.65% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $16.0 million in 2021, then crashed by 66.18% to $5.4 million in 2022, then plummeted by 136.65% to -$2.0 million in 2023, then surged by 36.57% to -$1.3 million in 2024, then soared by 97.45% to -$32000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Operating Expenses are -$32000.0 (Q4 2025), $2.5 million (Q3 2025), and $2.0 million (Q2 2025).